Published online before print June 21, 2001, doi: 10.1161/hh1301.092661
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2001 American Heart Association, Inc.
Clinical Research |
Increased Expression of Protease-Activated Receptor-2 (PAR2) and PAR4 in Human Coronary Artery by Inflammatory Stimuli Unveils Endothelium-Dependent Relaxations to PAR2 and PAR4 Agonists
From the Department of Pharmacology (J.R.H., T.M.C.), University of Melbourne, Victoria, Australia, and the Clinical Pharmacology and Therapeutics Unit (A.G.F.), Department of Medicine, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia.
Correspondence to Tom Cocks, PhD, Department of Pharmacology, University of Melbourne, Victoria 3010, Australia. E-mail thomasmc{at}unimelb.edu.au
Abstract
Abstract—Protease-activated
receptor (PAR)1 and PAR2 are expressed on vascular
endothelial cells and mediate
endothelium-dependent relaxation in several species,
and PAR4 agonists cause similar responses in rat aortas. To date, only
PAR1 has been reported to mediate relaxation of human arteries despite
endothelial cell expression of both PAR1 and PAR2 in
these tissues. Because inflammatory stimuli increase PAR2 expression in
human endothelial cells in culture, the present
study investigated the effect of similar stimuli on PARs in human
isolated coronary arteries (HCAs). In HCA ring segments
suspended for isometric tension measurements, the selective
PAR1-activating peptide, TFLLR (0.01 to 10 µmol/L), caused
endothelium-dependent relaxation of precontracted
preparations. Little or no change in vascular tension was elicited by
either the PAR2- or PAR4-activating peptides, SLIGKV and GYPGQV,
respectively (up to 100 µmol/L). Exposure of HCAs to interleukin
(IL)-1
(1 ng/mL, 12 hours) or tumor necrosis factor- (3 nmol/L,
12 hours) did not affect PAR1 expression but increased PAR2 and
PAR4 mRNA levels by 
5- and 4-fold, respectively, as determined by
quantitative polymerase chain reaction. Similar IL-1 treatment did
not affect TFLLR-induced relaxations but revealed significant
endothelium-dependent relaxations to SLIGKV (100
µmol/L, 61.4±6.7%) and GYPGQV (100 µmol/L, 34.8±6.4%). These
studies are the first to demonstrate functional PAR2 and PAR4 in human
arteries in situ. The selective upregulation of PAR2 and PAR4
expression and the increased vascular response in HCAs after exposure
to inflammatory stimuli suggest a role for these
endothelial receptors during inflammation.
Key Words: endothelium • human coronary arteries • protease-activated receptors
Protease-activated receptors (PARs) located on vascular smooth muscle and/or endothelial cells have been implicated in the control of vascular tone and hemostasis, particularly during inflammatory states (see reviews1 2 3 ). PARs are G-protein–coupled receptors activated by particular serine proteases via a unique mechanism as follows: site-specific proteolysis of the amino-terminal exodomain of the receptor exposes a neo-N-terminal, which acts as a self-activating "tethered" ligand.4 5 Four PARs have been cloned. PAR14 and PAR36 are essentially thrombin receptors. PAR27 is activated most sensitively by trypsin and can be activated to a lesser extent by blood-borne enzymes, such as mast cell tryptase8 9 and coagulation factor VIIa.10 The known enzyme activators of PAR4 include thrombin, trypsin, and neutrophil-derived cathepsin G.11 12 Intriguingly, at least for mouse receptors expressed in COS-7 cells, activation of PAR4 by thrombin requires PAR3 as a thrombin-binding cofactor.13 Because each cloned PAR is activated by trypsin (PAR2) or both thrombin and trypsin (PAR1, PAR3, and PAR4), it is fortunate that PARs, with the exception of PAR3,6 can be selectively activated by synthetic peptides corresponding to the distinct tethered ligand sequences of each receptor.4 6 7 12
Emerging literature suggests that endothelial PARs play important roles during vascular inflammation and tissue injury.1 2 14 15 16 PAR1 and PAR2 are present on smooth muscle and/or endothelial cells, where they mediate direct contraction and NO-mediated endothelium-dependent relaxation, respectively, depending on the preparation, species, and disease state of the tissue. For example, activation of PAR1 (with thrombin or the PAR1-activating peptide, SFLLRN) or PAR2 (with trypsin or the PAR2-activating peptide, SLIGRL) induces endothelium-dependent relaxation of the pig coronary artery17 and rat aorta.18 However, in endothelium-denuded pig coronary arteries, none of these PAR agonists alters vascular tension.17 By contrast, activators of PAR1, but not PAR2, cause contraction of the endothelium-denuded rat aorta.18 This differs again from the mouse renal artery, in which activators of PAR2 not only cause typical endothelium-dependent relaxation in endothelium-intact vessels but also induce smooth muscle contraction of endothelium-denuded preparations.19 In addition to PAR1 and PAR2, functional PAR3 and PAR4 have been reported on endothelial cells of rat brain capillaries and rat aorta, respectively.20 21
Although our insight into the roles of vascular PARs in animal models is progressing, little is known about PARs in human vasculature. Endothelial localization of PAR1 mRNA via in situ hybridization has been described in nonatherosclerotic hepatic arteries and in both endothelial and smooth muscle cells of atherosclerotic arteries.22 This finding is supported by functional studies on human isolated coronary arteries (HCAs), which demonstrated PAR1-mediated endothelium-dependent relaxation of nonatherosclerotic arteries and a lack of contraction to PAR1 agonists in artery preparations with or without functional endothelium23 24 but an increased contraction associated with an increased degree of atheroma in endothelium-disrupted artery segments.23 For PAR2, immunoreactivity has been reported in the endothelium and smooth muscle of HCAs.25 Functionally, PAR2-activating peptides induce calcium fluxes in human umbilical vein endothelial cells (HUVECs)8 and mitogenic responses in human aortic smooth muscle cells in culture.26 However, PAR2 agonists cause neither contraction nor relaxation of HCAs.24
We wondered whether the discrepancy between PAR2 expression
and the ability of PAR2 agonists to cause changes in human vascular
tone is due to low receptor number. Because the inflammatory
cytokines interleukin (IL)-1 and tumor necrosis factor
(TNF)- increase PAR2 expression in
HUVECs27 and because similar
inflammatory stimuli ameliorate the hypotensive response to PAR2
activation in the rat in
vivo,28 the present
study investigated whether exposure of HCAs to inflammatory stimuli, in
vitro, would unveil an endothelium-dependent relaxation
to PAR2 activation in this tissue. Also, because there are no reports
of PAR3 or PAR4 in human arteries in situ, we investigated the presence
of these receptors in HCAs.
The present study detected PAR1, PAR2, and PAR4 mRNAs in
HCAs by polymerase chain reaction (PCR) and localized
immunoreactivities for PAR1 and PAR2 to HCA endothelial
cells. Despite the expression of three PARs, only agonists of PAR1
induced changes in vascular tone in HCAs in the absence of inflammatory
stimuli. Exposure of HCAs to either IL-1 or TNF- significantly
increased the expression of both PAR2 and PAR4, as determined by
quantitative PCR, which unveiled endothelium-dependent
relaxations in response to agonists of these receptors. The present
study provides the first evidence of functional PAR2 and PAR4 in human
arteries in situ and suggests a role for these
endothelial cell receptors during vascular
inflammation.
Materials and Methods
Materials
PAR1 and PAR2 antisera were gifts from Prof Lawrence
Brass (University of Pennsylvania, Philadelphia). Anti-mouse antiserum
and FITC-streptavidin were from Amersham
Pharmacia Biotech; U46619 and nifedipine, from
Sapphire Bioscience; (-)-isoprenaline, substance P (acetate salt),
and -thrombin (bovine serum), from Sigma
Chemical Co; IL-1 and TNF- (both recombinant, human), from
Endogen; and trypsin (bovine pancreas), from Worthington Biochemical.
TFLLR, SLIGKV, and GYPGQV were synthesized with carboxyl-terminal
amidation and purified to 95% via high-performance liquid
chromatography by
Auspep.
Human Coronary Arteries
With informed patient consent and ethics approval
from The Alfred Hospital and University of Melbourne Ethics Committees,
epicardial coronary arteries were dissected from explanted
hearts of 12 patients (9 men and 3 women, aged 45.3±5.1 years, range
28 to 61 years) undergoing transplantation at The Alfred Hospital
(Melbourne, Australia) because of dilated congestive
cardiomyopathy (n=6), restrictive
cardiomyopathy (n=3), ischemic heart
disease (n=2), or septal defects (n=1). Three-millimeter-long
arterial ring segments that were macroscopically free of
atheromatous plaques (endothelium was
mechanically removed in some) were prepared and (1) frozen in liquid
nitrogen and stored at -70°C for RNA extraction, (2) fixed in 4%
paraformaldehyde (4°C overnight) for
immunohistochemistry, (3) incubated at 37°C/5%
CO2 for 12 hours (CO2
incubator, Forma Scientific) in 5 mL Krebs solution in the absence or
presence of IL-1 (1 ng/mL) or TNF- (3 nmol/L), or (4) immediately
mounted in organ chambers for isometric tension
measurement.
Polymerase Chain Reaction
Total RNA was isolated and subjected to DNase
digestion by using the RNeasy Mini Kit
(Qiagen). cDNA synthesis was performed at 42°C
for 1 hour with 100 ng total RNA, 1 µmol/L
poly(dT)12–16 primers, and 200 U Moloney
murine leukemia virus reverse transcriptase with use of the First
Strand Synthesis Kit (Promega). For
"conventional" PCR, cDNA was amplified by a "touchdown" PCR
method29 to detect
transcripts under high-stringency hybridization conditions, with the
use of 5 ng cDNA, 0.5 µmol/L specific primers
(Table 1
), 0.2 mmol/L dNTPs, 2.5 U Taq DNA polymerase,
10 mmol/L Tris HCl (pH 8.3), 50 mmol/L KCl, and 1.5
mmol/L MgCl2 and with heating to 94°C for 3
minutes, followed by 5 cycles of 94°C, 70°C, and 72°C (each for
30 seconds) and then 35 cycles of 94°C, 55°C, and 72°C (each for
30 seconds), and, finally, 72°C for 5 minutes. Quantitative PCR was
performed with an ABI Prism 7700 Sequence Detection System
(Applied Biosystems) according to the
manufacturer’s instructions. Specific primer sequences were used in
combination with internal probes, each labeled at the 5' end with the
reporter dye 6-carboxyfluorescein and at the 3' end with
the quencher dye 6-carboxytetramethylrhodamine
(Table 2). Amplification was performed for 40 cycles of
95°C for 15 seconds and 60°C for 60 seconds.
|
|
Immunohistochemistry
Paraformaldehyde-fixed HCA was
washed in PBS, placed in sucrose solution (15% [wt/vol] in PBS) at
4°C overnight, embedded in OCT compound
(Sakura Finetek), and frozen in liquid nitrogen. PAR1 and PAR2
were localized by using previously characterized monoclonal antibodies
produced in mice immunized with peptides corresponding to the
amino-terminus of human PAR1
(S42FLLRNPNDKYEPF55,
1:100) or human PAR2
(S37LIGKVDGTSHVTG50,
1:20) (see Molino et al8 ).
Primary antisera were labeled with a biotinylated sheep anti-mouse
antiserum (1:100, 1 hour) and FITC-conjugated streptavidin (1:20, 1
hour).
Isometric Tension Measurements
HCAs were mounted for isometric tension measurement
as previously described.24
After a standard equilibration
procedure,24 including
treatment with nifedipine (0.3 µmol/L) to inhibit
characteristic spontaneous contractile
activity,30 HCAs were
contracted to 50% of their maximum contraction to 125 mmol/L
KCl with U46619, and cumulative half-log increases in the concentration
of PAR agonists were added. The maximum
endothelium-dependent and -independent relaxations were
determined by adding substance P (3 nmol/L) and isoprenaline (1
mmol/L), respectively.
Statistical Analysis
Changes in isometric tension were normalized as
percent tissue response to 1 µmol/L isoprenaline.
pEC50 values represent the negative
logarithm of the molar concentration that caused 50% of the maximum
response. mRNA levels are expressed as fold increase in PAR mRNA
normalized against 18S rRNA as the within-tissue control. All data are
mean±SEM. Differences in mean relaxations and mRNA levels were tested
for significance (P<0.05) by
ANOVA, with post hoc analyses for multiple
comparisons.
Results
Polymerase Chain Reaction
Conventional PCR analyses on mRNA extracted
from endothelium-intact HCAs resulted in amplification
of a single fragment of predicted size
(Table 1
) for PAR1, PAR2, and PAR4 (n=4 artery
segments, from four patients)
(Figure 1). By contrast, no PCR fragment was detected for
PAR3 in these tissues (n=4 artery segments, from four patients)
(Figure 1). When human cardiac muscle was used as a positive
control for PAR3 expression,6
a single PCR product of predicted size was detected (n=2 artery
segments, from two patients)
(Figure 1).
|
In similar PCR analyses on mRNA extracted from HCA
preparations from which the endothelium had been
removed, we again observed the expected PCR products for PAR1 and
PAR4 (n=2 artery segments, from two patients)
(Figure 1). By contrast, the PAR2 PCR fragment detected in
endothelium-intact HCAs was no longer evident (n=2
artery segments, from two patients)
(Figure 1). We confirmed the effective removal of
endothelial cells in these
"endothelium-denuded" HCA segments by using
specific primers for endothelial constitutive NO
synthase (ecNOS), which amplified a product of the expected size in
endothelium-intact HCA segments but not in
endothelium-denuded HCA segments (n=2 artery segments,
from two patients)
(Figure 1).
Because PAR1, PAR2, and PAR4 are expressed in the vasculature, it was difficult to obtain negative tissue controls for the expression of these receptors. Thus, PCR products for PAR1, PAR2, and PAR4 were detected in vascularized human tissues, such as testis, thyroid, and muscle of cardiac, ocular, and abdominal origin (data not shown). However, no products were observed if cDNA from rat heart was used in the PCR reaction (data not shown). The possibility of contamination by genomic DNA was unlikely because isolated RNA was subjected to DNase treatment before transcription. Furthermore, no PCR products were detected when PCR was performed on untranscribed RNA (data not shown).
Immunohistochemistry
Punctate PAR1 and PAR2 immunoreactivities were
localized to the endothelium with little, if any,
staining with either antisera detectable in the smooth muscle
(Figure 2).
|
Quantitative PCR
Treatment of endothelium-intact HCA
segments with IL-1 (1 ng/mL, 12 hours) caused a significant
(P<0.05) 5- and 4-fold
increase in mRNA expression for PAR2 and PAR4, respectively, as
measured by real-time quantitative PCR (n=3 artery segments, from three
patients)
(Figure 3). By contrast, mRNA levels for PAR1 were virtually
unaffected (1.3-fold increase) by similar treatment with IL-1
(n=3 artery segments, from three patients)
(Figure 3). Treatment of HCAs with TNF- (3 nmol/L) caused
a similar increase in PAR2 (4-fold) and PAR4 (3-fold) mRNA levels
but, again, had little effect on PAR1 expression (1.3-fold increase
in mRNA; n=3 artery segments, from three patients)
(Figure 3). The effects of IL-1 and TNF- were likely
specific because boiling these cytokines before treatment of
HCAs abolished their effect (data not shown).
|
Isometric Tension Measurements
In endothelium-intact HCAs mounted for
isometric tension measurement immediately after dissection, the
selective PAR2-activating peptide, SLIGKV, failed to cause relaxation
of contracted preparations at concentrations of up to 100 µmol/L
(data not shown). In similar endothelium-intact HCA
preparations incubated in the presence of IL-1 (1 ng/mL, 12 hours),
SLIGKV induced significant relaxations, with a threshold at 3
µmol/L and a maximum at 100 µmol/L of 61.4±6.7% (n=10 artery
segments, from five patients)
(Figure 4). Almost no relaxation to SLIGKV was observed in
endothelium-intact HCA preparations incubated under
similar conditions but in the absence of IL-1
(Figure 4). Also, SLIGKV-induced relaxations were abolished
by removal of the endothelium immediately after the
IL-1 treatment period
(Figure 4).
|
Similar to the results obtained with SLIGKV, the selective
PAR4-activating peptide, GYPGQV (up to 100 µmol/L), failed to relax
HCAs mounted for isometric tension measurement immediately after
dissection (data not shown). GYPGQV also caused no relaxation of
endothelium-intact HCAs incubated for 12 hours in the
absence of IL-1 but caused significant relaxations in tissues
incubated under the same conditions but in the presence of IL-1 (1
ng/mL, 34.8±6.4% at 100 µmol/L; n=4 artery segments, from two
patients)
(Figure 4). GYPGQV-induced relaxations were abolished by
removal of the endothelium after the incubation period
(Figure 4).
In contrast to SLIGKV- and GYPGQV-induced responses,
relaxations caused by the selective PAR1-activating peptide, TFLLR,
were not different between endothelium-intact HCAs
incubated in the absence (pEC50 6.4±0.2,
maximal relaxation 89.0±2.6%) and presence
(pEC50 6.3±0.1, maximal relaxation 87.8±2.5%)
of IL-1 (n=8 artery segments, from four patients)
(Figure 4).
A similar upregulation of
endothelium-dependent relaxations to SLIGKV and GYPGQV,
but not TFLLR, was observed after treatment of HCAs with TNF- (3
nmol/L) (n=4 artery segments, from two patients) (data not
shown).
Relaxations to both SLIGKV and GYPGQV in
IL-1–treated HCAs were abolished by combined treatment with the
ecNOS inhibitor,
NG-nitro-L-arginine
(L-NOARG, 100 µmol/L), and the cyclooxygenase
inhibitor, indomethacin (3 µmol/L) (n=4
artery segments, from two patients)
(Figure 4). Also, TFLLR, SLIGKV, and GYPGQV all failed to
cause relaxation of endothelium-denuded HCAs incubated
with either IL-1 or TNF- (data not shown).
Finally, TFLLR, SLIGKV, and GYPGQV caused no significant
contraction under any of the conditions investigated in the present
study. Thus, none of the PAR-activating peptides, at concentrations of
up to 100 µmol/L, contracted endothelium-intact or
-denuded HCAs incubated with or without IL-1 or TNF-, either in
the absence or presence of U46619-induced tone (data not shown).
Furthermore, the failure of TFLLR, SLIGKV, and GYPGQV to contract HCAs
persisted in the absence of nifedipine (data not
shown).
Discussion
The main finding of the present study was that exposure of HCAs to inflammatory stimuli selectively increased PAR2 and PAR4 expression, which unveiled endothelium-dependent relaxations to agonists of these receptors. To our knowledge, the present study is the first to report functional PAR2 and PAR4 in human arteries and, indeed, is the first to describe the presence of PAR4 in human vasculature in situ.
We previously reported endothelium-dependent relaxation of HCAs by thrombin and the PAR1-activating peptide, SFLLRN.24 The present study first confirmed that the more selective PAR1-activating peptide, TFLLR,31 caused similar relaxation of HCAs. By contrast with TFLLR, the selective PAR2-activating peptide, SLIGKV, failed to relax contracted HCAs, a finding that we have previously reported.24 Despite this, two findings from our present study indicated that PAR2 was expressed on HCA endothelium. First, PAR2 immunoreactivity was localized specifically to the endothelial cell layer. Second, PAR2 mRNA was readily detected in endothelium-intact HCAs but not in segments of artery from which the endothelium had been removed. Importantly, we used PCR for ecNOS, the expression of which is limited to endothelial cells in the vasculature,32 to confirm the absence of contaminating endothelium in HCA segments from which the endothelium was presumed to have been effectively removed. Our finding that PAR2 is expressed only in the endothelium of HCAs differs from the study of Molino et al,25 who reported PAR2 immunoreactivity on smooth muscle as well as endothelial cells in this tissue. The reason for the discrepancy between the present study and that of Molino et al is unclear, although one possibility may involve differences in the disease state of the tissue used in each study. For example, disease-related differences in receptor expression have been reported for PAR1. Thus, PAR1 expression was limited to the endothelium of nonatherosclerotic arteries but was observed in both endothelial and smooth muscle cells in atheromatous arteries.22 Regardless of these differences in the detection of PAR2 expression on smooth muscle, the present study and that of Molino et al have clearly shown that unlike the expression in arteries of other species, the expression of PAR2 on the endothelium of HCAs does not necessarily translate to PAR2-mediated endothelium-dependent relaxation of this tissue.
In an attempt to reconcile the apparent discrepancy between
PAR2 expression and function on HCA endothelial cells,
we sought to investigate the effects of inflammatory stimuli on this
receptor. Previously, Nystedt et
al27 showed that treatment
of HUVECs with IL-1, TNF-, or lipopolysaccharide
increased mRNA and cell-surface protein levels for PAR2, but not PAR1.
In addition, Cicala et al28
reported that treatment of rats in vivo with lipopolysaccharide
similarly increased PAR2 expression in the aorta and jugular vein,
which was manifested as an increased sensitivity to the dilator
response of PAR2 agonists in rat vasculature in vitro and in vivo.
Again, this upregulation in response to an inflammatory stimulus was
selective for PAR2 over
PAR1.28 A similar selective
upregulation of PAR2 mRNA in HCAs treated with either IL-1 or
TNF- was observed in the present study with the use of
quantitative PCR. The 4- to 5-fold increase in PAR2 mRNA observed in
the present study occurred at the same concentrations of the two
cytokines (3 nmol/L and 1 ng/mL for TNF- and IL-1,
respectively) and within the same time frame (12 hours) that gave an
3-fold increase in PAR2 mRNA in the study of Nystedt et al. Although
Nystedt et al found that 1 ng/mL IL-1 was sufficient to cause
maximum increase in PAR2 mRNA (13-fold increase), this response
occurred after 48 hours of IL-1 treatment. Unfortunately, such an
incubation period was not possible in the present study, inasmuch
as preliminary experiments determined that
endothelium-dependent relaxation of HCA ring
preparations declined with incubations beyond 12 hours. This is an
important experimental limitation of incubating isolated tissues,
because we also observed that a 10-fold increase in IL-1
concentration (to 10 ng/mL) caused no greater induction of PAR2 mRNA
expression or SLIGKV-induced vascular relaxation (not shown).
Therefore, the 60% relaxation caused by 100 µmol/L SLIGKV appears
to be the maximum response that we can induce in this tissue with
IL-1. However, on the basis of the time course studies of Nystedt et
al in cultured HUVECs, it seems likely that prolonged (ie, >12-hour)
exposure to inflammatory cytokines, such as that occurring
during pathophysiological conditions in vivo, will
further increase the sensitivity to PAR2 agonists.
A pattern of vascular reactivity similar to that observed
for PAR2 was seen with PAR4. As was the case with SLIGKV, the selective
PAR4-activating peptide, GYPGQV, failed to cause relaxation of
contracted HCAs at concentrations of up to 100 µmol/L. As with PAR2,
PAR4 mRNA was readily detected in HCAs, although in contrast to PAR2,
PAR4 mRNA was also detected in endothelium-denuded HCA
segments. Because antibodies directed against PAR4 were not available
at the time of the present study, definitive evidence for PAR4
expression on HCA endothelial cells could not be
provided. However, our finding (ie, that the upregulation of vascular
relaxation to GYPGQV after exposure of HCAs to IL-1 or TNF- was
entirely dependent on the presence of functional
endothelium) suggests that like PAR2, PAR4 was
expressed in HCA endothelial cells. To our knowledge,
this is the first demonstration of the in situ localization and
functional description of PAR4 in the human vasculature. This result
supports an earlier study in which an NO-mediated
endothelium-dependent relaxation was observed in rat
aortas in response to PAR4-activating
peptides.21
Our hypothesis that relaxations of HCAs by agonists of PAR2
or PAR4 are due to upregulation of these receptors on
endothelial cells is supported by our observations that
both SLIGKV- and GYPGQV-induced relaxations were entirely dependent on
an intact endothelium and were abolished in the
presence of inhibitors of the synthesis of NO (L-NOARG) and
prostacyclin (indomethacin), the primary mediators of
endothelium-dependent relaxation in human
arteries.30 In addition, the
effects of IL-1 and TNF- are likely specific because they were
(1) blocked by boiling the cytokines before the treatment
period, (2) concentration-dependent and occurred at the same
concentration previously reported to cause similar effects, (3)
dependent on the presence of an intact endothelial cell
layer, and (4) selective for SLIGKV and GYPGQV, inasmuch as relaxations
to TFLLR, thrombin, and substance P were unaffected by similar
treatment regimes (not shown).
Upregulation of endothelial cell PAR2 in response to inflammatory stimuli has been taken to indicate that PAR2 is involved in the progression of vascular inflammatory diseases.3 However, as we have previously pointed out,1 the opposite could apply. Thus, PAR2 (and PAR4) upregulation may increase the protective barrier function of the endothelium and limit, for example, clotting and disseminating intravascular coagulation in proinflammatory conditions, such as sepsis and hypertension. It is interesting to note that in hypertension, although most other endothelium-dependent vasodilator function is diminished33 and although there is an increased potential for thrombosis,34 PAR2-mediated vasodilatation is preserved.35 Further evidence that endothelial PAR2 is anti-inflammatory, albeit indirect, comes from our earlier observation in porcine isolated coronary arteries. We found that proinflammatory enzymes, such as bacterial thermolysin, which disable PAR2 without causing receptor activation, trigger a novel translation-dependent mechanism for replenishment of the cell surface receptor, which is rapid and specific for PAR2 over PAR1.17 Therefore, vascular endothelial PAR2 (and possibly PAR4) is not only upregulated in inflammation, but novel mechanisms appear to exist to maintain PAR2 responsiveness during such conditions.
The inability of agonists of PAR1, PAR2, or PAR4 to induce contraction of HCAs under any of the conditions investigated in the present study suggests that smooth muscle cell PARs play a limited role in contracting human arteries. Although PAR1-mediated contractions occur in HCAs displaying signs of atheroma,23 smooth muscle cell PARs may be involved in functions other than the regulation of vascular tone, such as smooth muscle growth and differentiation,36 in the absence of atheroma.
Finally, the present study raises the possibility of a lack of PAR3 in the human vasculature. The inability of synthetic PAR3-activating peptides to activate this receptor6 prohibits us from investigating PAR3 function in this way. However, we were unable to detect PAR3 mRNA in HCAs. Furthermore, desensitization to the PAR1-activating peptides, SFLLRN and TFLLR (which cannot activate PAR3 at the concentrations used in the present study6 12 ), abolished subsequent responses to thrombin (the most potent known activator of PAR36 ) (J.R. Hamilton, T.M. Cocks, unpublished data, 2000). These findings contrast with those of previous reports that showed functional PAR3 in HUVECs via measurement of intracellular calcium concentration changes.37 The discrepancy between our results and those obtained in HUVECs remains unexplained but may simply reflect differences between HUVEC and native human endothelial cells or differences in PAR3 expression between venous and arterial endothelial cells, such as that reported for other PARs.25
In conclusion, the present study is the first to demonstrate functional PAR2 and PAR4 in human vasculature in situ. We suggest that under physiological conditions, circulating thrombin activates PAR1 to relax underlying smooth muscle. In contrast with PAR1, endothelial PAR2 and PAR4 are expressed in low levels and do not contribute to serine protease regulation of vasodilator tone in the coronary bed. However, in pathological conditions in which inflammatory cytokines are released, such as ischemia/reperfusion injury,38 atherosclerosis,39 and, perhaps, hypertension,40 PAR2 and PAR4 are upregulated and may now respond to (patho)physiological concentrations of activating enzymes and contribute to endothelium-dependent vasodilatation. PAR2 is insensitive to thrombin, and at least for the mouse receptor, PAR4 cannot be activated by thrombin in the absence of PAR3.13 Because PAR3 was not expressed in HCAs, PAR2 and PAR4 are likely nonthrombin PARs in this tissue. On this assumption, we suggest that vascular inflammation promotes the switching of endothelial cell PARs from being thrombin sensitive under physiological conditions to being thrombin insensitive during vascular inflammation. As such, the inflammatory stimuli–induced upregulation of PAR2 and PAR4 in HCAs may indicate that these receptors are protective when expressed on endothelial cells and that they regulate vascular tone in inflammation and/or vascular injury.
Acknowledgments
This study was supported by the
National Health and Medical Research Council of Australia (Dr Cocks).
We gratefully acknowledge the assistance of the Heart and Lung
Transplant Unit at The Alfred Hospital, Melbourne, Australia, for their
generous assistance in obtaining the human tissue used in this study.
The authors also wish to thank Lerna Gulluyan for assistance with the
quantitative PCR studies and Dr Alastair Stewart for providing the
IL-1 and TNF-.
Footnotes
Original received April 10, 2000; resubmission received April 4, 2001; revised resubmission received May 10, 2001; accepted May 10, 2001.
References
1. Cocks TM, Moffatt JD. Protease-activated receptors: sentries for inflammation? Trends Pharmacol Sci. 2000;21:103–108.
2. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258–264.
3. Déry O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998;274:C1429–C1452.
4. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057–1068.
5. Chen J, Ishii M, Wang L, Ishii K, Coughlin SR. Thrombin receptor activation: confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative liganding mode. J Biol Chem. 1994;269:16041–16045.
6. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature. 1997;386:502–506.
7. Böhm SK, Kong W, Brömme D, Smeekens SP, Anderson DC, Connolly A, Kahn M, Nelken NA, Coughlin SR, Payan DG, Bunnett NW. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996;314:1009–1016.
8. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272:4043–4049.
9. Fox MT, Harriott P, Walker B, Stone SR. Identification of potential activators of proteinase-activated receptor-2. FEBS Lett. 1997;417:267–269.
10. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000;97:5255–5260.
11. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000;275:6819–6823.
12. Xu W, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Nat Acad Sci U S A. 1998;95:6642–6646.
13. Nakanishi-Matsui M, Zheng Y-W, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404:609–613.
14. Damiano BP, D’Andrea MR, de Garavilla L, Cheung W-M, Andrade-Gordon P. Increased expression of protease-activated receptor-2 (PAR-2) in balloon-injured rat carotid artery. Thromb Haemost. 1999;81:808–814.
15. Vergnolle N. Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol. 1999;163:5064–5069.
16. Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, Foy D, Hafezi-Moghadam A, Ley K. Delayed onset of inflammation in protease-activated receptor-2-deficient mice. J Immunol. 2000;165:6504–6510.
17. Hamilton JR, Chow JM, Cocks TM. Protease-activated receptor-2 turnover stimulated independently of receptor activation in porcine coronary endothelial cells. Br J Pharmacol. 1999;127:617–622.
18. Magazine HI, King JM, Srivastava KD. Protease activated receptors modulate aortic vascular tone. Int J Cardiol. 1996;53:S75–S80.
19. Moffatt JD, Cocks TM. Endothelium-dependent and -independent responses to protease-activated receptor-2 (PAR-2) activation in mouse isolated renal arteries. Br J Pharmacol. 1998;125:591–594.
20. Bartha K, Domotor E, Lanza F, Adam-Vizi V, Machovich M. Identification of thrombin receptors in rat brain capillary endothelial cells. J Cereb Blood Flow Metab. 2000;20:175–182.
21. Hollenberg MD, Saifeddine M, Al-Ani B, Gui Y. Proteinase-activated receptor 4 (PAR4): action of PAR4-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR1 and PAR2. Can J Physiol Pharmacol. 1999;77:458–464.
22. Nelken NA, Soifer SJ, O’Keefe J, Vu T-K, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614–1621.
23. Ku DD, Dai J. Expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro. J Cardiovasc Res. 1997;30:649–657.
24. Hamilton JR, Nguyen PB, Cocks TM. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res. 1998;82:1306–1312.
25. Molino M, Raghunath PN, Kuo A, Ahuja M, Hoxie JA, Brass LF, Barnathan ES. Differential expression of functional protease-activated receptor-2 (PAR-2) in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1998;18:825–832.
26. Bono F, Lamarche I, Herbert JM. Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2. Biochem Biophys Res Commun. 1997;241:762–764.
27. Nystedt S, Ramakrishnan V, Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. J Biol Chem. 1996;271:14910–14915.
28. Cicala C, Pinto A, Bucci M, Sorrentino R, Walker B, Harriot P, Cruchley A, Kapas S, Howells GL, Cirino G. Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Circulation. 1999;99:2590–2597.
29. Major BJ, Cures A, Frauman AG. The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: a link to the pathogenesis of Graves’ ophthalmopathy. Biochem Biophys Res Commun. 1997;230:493–496.
30. Stork AP, Cocks TM. Pharmacological reactivity of human epicardial coronary arteries: characterization of relaxation responses to endothelium-derived relaxing factor. Br J Pharmacol. 1994;113:1099–1104.
31. Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD. Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther. 1999;288:358–370.
32. Pollock JS, Nakane M, Buttery LDK, Martinez A, Springall D, Polak JM, Förstermann U, Murad F. Characterization and localization of endothelial nitric oxide synthase using specific monoclonal antibodies. Am J Physiol. 1993;265:C1379–C1387.
33. Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. Hypertens Res. 1995;18:87–98.
34. Tomiyama H, Kimura Y, Mitsuhashi H, Kinouchi T, Yoshida H, Kushiro T, Doba N. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension. 1998;31:321–327.
35. Sobey CG, Moffatt JD, Cocks TM. Evidence for selective effects of chronic hypertension on cerebral artery vasodilatation to protease-activated receptor-2 activation. Stroke. 1999;30:1933–1941.
36. Ahn H-S, Foster C, Boykow G, Stamford A, Manna M, Graziano M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol. 2000;60:1425–1434.
37. Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, Bahou WF. The human proteinase-activated receptor-3 (PAR-3) gene: identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem. 1998;273:15061–15068.
38. Nose PS. Cytokines and reperfusion injury. J Card Surg. 1993;8:305–308.
39. Nilsson J. Cytokines and smooth muscle cells in atherosclerosis. Cardiovasc Res. 1993;27:1184–1190.
40. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J. 1995;8:2129–2138.
This article has been cited by other articles:
 |
|
 |
|
  M. Megyeri, V. Mako, L. Beinrohr, Z. Doleschall, Z. Prohaszka, L. Cervenak, P. Zavodszky, and P. Gal Complement Protease MASP-1 Activates Human Endothelial Cells: PAR4 Activation Is a Link between Complement and Endothelial Function J. Immunol., September 1, 2009; 183(5): 3409 - 3416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Borissoff, H. M.H. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res, June 1, 2009; 82(3): 392 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Suzuki, E. D. Motley, K. Eguchi, A. Hinoki, H. Shirai, V. Watts, L. N. Stemmle, T. A. Fields, and S. Eguchi Distinct Roles of Protease-Activated Receptors in Signal Transduction Regulation of Endothelial Nitric Oxide Synthase Hypertension, February 1, 2009; 53(2): 182 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Chin, W. Y. Lee, A. Nusrat, N. Vergnolle, and C. A. Parkos Neutrophil-mediated Activation of Epithelial Protease-Activated Receptors-1 and -2 Regulates Barrier Function and Transepithelial Migration J. Immunol., October 15, 2008; 181(8): 5702 - 5710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rallabhandi, Q. M. Nhu, V. Y. Toshchakov, W. Piao, A. E. Medvedev, M. D. Hollenberg, A. Fasano, and S. N. Vogel Analysis of Proteinase-activated Receptor 2 and TLR4 Signal Transduction: A NOVEL PARADIGM FOR RECEPTOR COOPERATIVITY J. Biol. Chem., September 5, 2008; 283(36): 24314 - 24325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O'Brien, J. J Morrison, and T. J Smith Expression of Prothrombin and Protease Activated Receptors in Human Myometrium During Pregnancy and Labor Biol Reprod, January 1, 2008; 78(1): 20 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ramachandran, L. R. Sadofsky, Y. Xiao, A. Botham, M. Cowen, A. H. Morice, and S. J Compton Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4 Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L788 - L798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hirano The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 27 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Lidington, R. Steinberg, A. R. Kinderlerer, R. C. Landis, M. Ohba, A. Samarel, D. O. Haskard, and J. C. Mason A role for proteinase-activated receptor 2 and PKC-{epsilon} in thrombin-mediated induction of decay-accelerating factor on human endothelial cells Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1437 - C1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Roviezzo, M. Bucci, V. Brancaleone, A. Di Lorenzo, P. Geppetti, S. Farneti, L. Parente, G. Lungarella, S. Fiorucci, and G. Cirino Proteinase-Activated Receptor-2 Mediates Arterial Vasodilation in Diabetes Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fujiwara, E. Jin, M. Ghazizadeh, and O. Kawanami Activation of PAR4 Induces a Distinct Actin Fiber Formation via p38 MAPK in Human Lung Endothelial Cells J. Histochem. Cytochem., September 1, 2005; 53(9): 1121 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Noorbakhsh, N. Vergnolle, J. C. McArthur, C. Silva, M. Vodjgani, P. Andrade-Gordon, M. D. Hollenberg, and C. Power Proteinase-Activated Receptor-2 Induction by Neuroinflammation Prevents Neuronal Death during HIV Infection J. Immunol., June 1, 2005; 174(11): 7320 - 7329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. James, D. J. Collison, and G. Duncan Characterization and Functional Activity of Thrombin Receptors in the Human Lens Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 925 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fu, A. P. Naren, X. Gao, G. U. Ahmmed, and A. B. Malik Protease-activated Receptor-1 Activation of Endothelial Cells Induces Protein Kinase C{alpha}-dependent Phosphorylation of Syntaxin 4 and Munc18c: ROLE IN SIGNALING P-SELECTIN EXPRESSION J. Biol. Chem., February 4, 2005; 280(5): 3178 - 3184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Busch, I. Seitz, B. Steppich, S. Hess, R. Eckl, A. Schomig, and I. Ott Coagulation Factor Xa Stimulates Interleukin-8 Release in Endothelial Cells and Mononuclear Leukocytes: Implications in Acute Myocardial Infarction Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 461 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hazarika, M. F. McCarty, V. G. Prieto, S. George, D. Babu, D. Koul, M. Bar-Eli, and M. Duvic Up-regulation of Flotillin-2 Is Associated with Melanoma Progression and Modulates Expression of the Thrombin Receptor Protease Activated Receptor 1 Cancer Res., October 15, 2004; 64(20): 7361 - 7369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K Chan, N. Vergnolle, M. D Hollenberg, and P.-Y. von der Weid Proteinase-activated receptor 2 activation modulates guinea-pig mesenteric lymphatic vessel pacemaker potential and contractile activity J. Physiol., October 15, 2004; 560(2): 563 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Napoli, F de Nigris, J L Wallace, M D Hollenberg, G Tajana, G De Rosa, V Sica, and G Cirino Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions J. Clin. Pathol., May 1, 2004; 57(5): 513 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. OSSOVSKAYA and N. W. BUNNETT Protease-Activated Receptors: Contribution to Physiology and Disease Physiol Rev, April 1, 2004; 84(2): 579 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pawlinski, B. Pedersen, G. Schabbauer, M. Tencati, T. Holscher, W. Boisvert, P. Andrade-Gordon, R. D. Frank, and N. Mackman Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia Blood, February 15, 2004; 103(4): 1342 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Lan, G. A. Stewart, R. G. Goldie, and P. J. Henry Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice Am J Physiol Lung Cell Mol Physiol, February 1, 2004; 286(2): L388 - L398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird Thrombin and Phenotypic Modulation of the Endothelium Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 41 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. E. Curry, M. Zeng, and R. H. Adamson Thrombin increases permeability only in venules exposed to inflammatory conditions Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2446 - H2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cicala, S. Morello, V. Vellecco, B. Severino, L. Sorrentino, and G. Cirino Basal nitric oxide modulates vascular effects of a peptide activating protease-activated receptor 2 Cardiovasc Res, November 1, 2003; 60(2): 431 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kataoka, J. R. Hamilton, D. D. McKemy, E. Camerer, Y.-W. Zheng, A. Cheng, C. Griffin, and S. R. Coughlin Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells Blood, November 1, 2003; 102(9): 3224 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, C.-H. Wang, R. D. Weisel, G. A. Jeffries, T. J. Anderson, and S. Verma Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II Circulation, October 28, 2003; 108(17): 2041 - 2048. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Major, R. J. Santulli, C. K. Derian, and P. Andrade-Gordon Extracellular Mediators in Atherosclerosis and Thrombosis: Lessons From Thrombin Receptor Knockout Mice Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 931 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. D'Andrea, M. R. Saban, N.-B. Nguyen, P. Andrade-Gordon, and R. Saban Expression of Protease-Activated Receptor-1, -2, -3, and -4 in Control and Experimentally Inflamed Mouse Bladder Am. J. Pathol., March 1, 2003; 162(3): 907 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Robin, R. Kharbanda, P. Mclean, R. Campbell, and P. Vallance Protease-Activated Receptor 2-Mediated Vasodilatation in Humans In Vivo: Role of Nitric Oxide and Prostanoids Circulation, February 25, 2003; 107(7): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Klarenbach, A. Chipiuk, R. C. Nelson, M. D. Hollenberg, and A. G. Murray Differential Actions of PAR2 and PAR1 in Stimulating Human Endothelial Cell Exocytosis and Permeability: The Role of Rho-GTPases Circ. Res., February 21, 2003; 92(3): 272 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Landis Aprotinin: Antithrombotic and Vasoactive Mechanisms of Action Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 307 - 312. [Abstract] [PDF]
|
|
|
|
|
|
A. F. Milia, M. B. Salis, T. Stacca, A. Pinna, P. Madeddu, M. Trevisani, P. Geppetti, and C. Emanueli Protease-Activated Receptor-2 Stimulates Angiogenesis and Accelerates Hemodynamic Recovery in a Mouse Model of Hindlimb Ischemia Circ. Res., August 23, 2002; 91(4): 346 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vergnolle, C. K. Derian, M. R. D'Andrea, M. Steinhoff, and P. Andrade-Gordon Characterization of Thrombin-Induced Leukocyte Rolling and Adherence: A Potential Proinflammatory Role for Proteinase-Activated Receptor-4 J. Immunol., August 1, 2002; 169(3): 1467 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maree and D. Fitzgerald PAR2 Is Partout and Now in the Heart Circ. Res., March 8, 2002; 90(4): 366 - 368. [Full Text] [PDF]
|
|
|
|
|
|
P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||